Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Mar 29;18(5):969–979. doi: 10.1158/1535-7163.MCT-18-0770

Figure 5. The combined effect of treatment with EP-100 and olaparib in vivo.

Figure 5.

(A) Photographs of representative mouse from each group. (B) The body weights, tumor weights, and nodule numbers in mice inoculated with HeyA8 cells that received a vehicle (control), 0.2 mg/kg EP-100 (intravenously twice a week), 50 mg/kg olaparib (intraperitoneally daily), or a combination of EP-100 and olaparib (olaparib was given 1 h after EP-100) (n=8 per group). (C) Immunohistochemical stains and (D) statistical analysis of paraffin slides for the expression of GnRH-R and γH2AX. Five fields per slide and at least three slides (5 slides for control, EP-100, and olaparib each group, 3 slides for combination group due to the limited tissue after treatment) were examined. Bars represent means ± standard deviation. * p < 0.05 and *** p < 0.001. Scale bar: 50 μM.